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Summary
Objective: Connective tissue growth factor (CTGF) has been implicated in regulation of chondrocyte differentiation at multiple steps and has
been implicated in the progression of diseases such as scleroderma and osteoarthritis. However, the pathways mediating the expression of
CTGF/CCN2 and related factors in cartilage are not fully understood. We have previously shown that the Rho family of proteins and the actin
cytoskeleton regulate both early and late chondrocyte differentiation.
Results: Here we demonstrate that several CTGF/Cyr61/Nov (CCN) family members are differentially affected by either inhibition of actin po-
lymerization (cytochalasin D treatment), promotion of actin polymerization (jasplakinolide treatment), inhibition of RhoA/rho kinase (ROCK)
signaling (Y27632 treatment) and Rac1 signaling. We also show that the Smad site in the CTGF/CCN2 promoter is responsive to both
Rac1 inhibition and cytochalasin D treatment, suggesting a role of TGFb/Smad signaling in mediating the effects of actin dynamics and Rac1.
Conclusion: Collectively, these data show that Rac1 and actin pathways control CTGF/CCN2 expression in chondrocytes which might be rel-
evant to both skeletal development and associated diseases such as osteoarthritis.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
Key words: Connective tissue growth factor, Actin cytoskeleton, Cartilage, Rho GTPases, Cell signaling, Rac1.Introduction
Chondrocytes are the cells that generate and maintain car-
tilage. During development, endochondral bone formation
requires a cartilage template that forms through a process
termed chondrogenesis. The cartilage anlagen that result
from this process are replaced by bone but the cartilaginous
growth plates persist until the end of puberty and are re-
sponsible for longitudinal growth1,2. The growth plate is
the cartilaginous region that remains on either side of the
primary ossiﬁcation center, where controlled proliferation
and differentiation of chondrocytes to hypertrophy are re-
sponsible for regulating ﬁnal bone length3. Although we
know many of the markers of chondrocyte differentiation
and proliferation, a better understanding of the signaling
pathways that regulate these markers is essential.
We have identiﬁed the Rho family of GTPases as impor-
tant novel signaling pathways that regulate chondrocyte dif-
ferentiation4. Our work and that of others has demonstrated
the importance of the actin cytoskeleton in regulating both
early differentiation of mesenchymal cells to chondrocytes
and differentiation to hypertrophy5e10. Speciﬁcally, Rac1
and Cdc42 appear to promote chondrocyte maturation ataContributed equally.
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406several stages, while RhoA signaling through the ROCK1/2
kinases delays both early chondrogenesis and hypertrophic
differentiation.
Connective Tissue Growth Factor (CTGF/CCN2) is a ma-
trix associated protein from the CCN family of proteins impli-
cated in cell adhesion, migration, proliferation, and
extracellular matrix (ECM) production in multiple cell
types11e14. CTGF/CCN2 is a member of a family that also
includes Cyr61/CCN1, Wisp1/CCN4, Wisp2/CCN5 and
Nov1/CCN315. CTGF/CCN2 and its family members are
normally only expressed in developing tissues16. However,
CTGF/CCN2 is known to be upregulated in pathological
conditions in adult tissues such as in ﬁbrotic diseases and
in various cancers, such as of the pancreas17e19. Further-
more, CTGF/CCN2 expression is found to be highly ex-
pressed in osteophytes of late stage osteoarthritis
suggesting a role in the progress of the disease20. In con-
trast to theses studies that suggest a pathological role of
CTGF/CCN2 in osteoarthritis, other experiments indicate
a protective or anabolic role21,22. Therefore, CTGF/CCN2
expression and regulation are of particular interest. It has
been determined that CTGF/CCN2 expression is regulated
by numerous molecules such as transforming growth factor
b1 (TGFb1)14,23, transforming growth factor b2 (TGFb2)24,
vascular endothelial growth factor (VEGF)25, and retinoic
acid26 in various cell types. CTGF/CCN2 is also upregu-
lated in response to mechanical stimuli27. Additionally, stud-
ies have demonstrated that rearrangement of focal
adhesion complexes, F-actin and cell morphology alter
CTGF/CCN2 expression16. These studies further suggest
407Osteoarthritis and Cartilage Vol. 17, No. 3a link between actin organization and regulation of CTGF/
CCN2 expression.
Rho GTPases are known to control the actin cytoskeleton
and are therefore potential regulators of CTGF/CCN2. Pre-
vious work has shown that inhibition of Rho signaling in-
duces Cyr61/CCN1 in smooth muscle cells28. Meanwhile,
CTGF/CCN2 has been found to be regulated by Rho signal-
ing in various cell types. Speciﬁcally, in smooth muscle
cells, constitutively active RhoA stimulates a 936 base
pair (bp) fragment of the CTGF/CCN2 promoter, but this
portion of DNA was unresponsive to Rac1 and Cdc42
signaling28.
Although CTGF/CCN2 and its family members show high
sequence homology, they each have distinct patterns of ex-
pression and thus biological function. In vitro studies have
demonstrated that Cyr61/CCN1 and CTGF/CCN2 inﬂuence
skeletal cell differentiation28e30 and deletion of the Ccn2
gene in mice conﬁrms these effects. Speciﬁcally, deletion
of Cyr61/CCN1 in vivo results in early embryonic death
due to placental defects29. Meanwhile, deletion of CTGF/
CCN2 in vivo results in perturbations of skeletal develop-
ment, with impaired ECM production and chondrocyte pro-
liferation30. In vitro, addition of CTGF/CCN2 promotes
chondrocyte differentiation31. It has been observed that
hypertrophic chondrocytes display strong CTGF/CCN2
expression in comparison to all other tissue types32, but lit-
tle is known about the signaling pathways that regulate
CTGF/CCN2 expression in chondrocytes. Our recent stud-
ies also indicate that CTGF/CCN2 promotes certain aspects
of chondrogenesis33.
Because the actin cytoskeleton and the Rho family of
GTPases have been implicated in regulating chondrocyte
differentiation and CTGF/CCN2 in other cell types, we
wanted to determine if actin dynamics or pathways that reg-
ulate actin affect CTGF/CCN2 expression in chondrocytes.
We demonstrate that CTGF/CCN2 expression is regulated
in response to changes in the actin cytoskeleton and that
the regulation of Rac1 signaling on CTGF/CCN2 expression
is mediated through TGFb/Smad signaling.Materials and methodsMATERIALSTimed pregnant CD1 mice were purchased from Charles River Laborato-
ries. All cell culture media components were from Invitrogen or Sigma unless
stated otherwise. All inhibitors were purchased from Calbiochem or Sigma.
All other reagents were of analytical grade from commercial suppliers.
Antibodies against CTGF/CCN2 (ab-6992) were from Abcam and the b-actin
antibody (A-544) was from Sigma.METHODSPrimary cell culture
Embryonic (E)15.5 mice long bones (radius, ulna, humerus, tibia, ﬁbula
and femur) were isolated, incubated in trypsin for 15 min and then digested
for 1.5 h in 1 mg/ml Collagenase P (Sigma), 10% fetal bovine serum (FBS) in
Dulbecco’s Modiﬁed Essential Media (DMEM) as described7. This heteroge-
neous population of chondrocytes was then plated in monolayer culture at
a density of 500,000 cells/well in a six-well dish (Nunc) and fed with media
containing 60% F12, 40% DMEM, 10% FBS, 0.1% Pen/Strep and 0.1% L-
glutamine. After 24 h, cells were treated with inhibitors, 10 mM Y27632
(inhibits both ROCKI and ROCKII34, speciﬁcity in chondrocytes shown previ-
ously5,8), 1 mM cytochalasin D (inhibits actin polymerization through binding
and sequestration of G-actin)35, 50 nM jasplakinolide (stabilizes and pro-
motes actin polymerization)36 or 50 mM of NSC23766 (inhibits Rac1 activity
by competing for binding with Rac1 guanine exchange factors on the activa-
tion site of Rac1)37 for 24 h. All inhibitors utilized demonstrated consistent
effects with previous experiments7,8,38 and were used from multiple different
lots, with little lot to lot variability.ATDC5 cell culture
ATDC5 cells were stably transfected with a Rac1, Cdc42 or empty ex-
pression vector and selected for by G418 as described previously5,6. Cells
were stimulated to differentiate with insulinetransferrineselenium (ITS)
(Sigma), grown over a period of 9 days and treated with dimethyl sulfoxide
(DMS) (control) or 1 mM cytochalasin D.
Rac1fl/fl cells
E11.5 mice limb buds were isolated from CD1 (wild-type) or Rac1fl/fl
mice39 and digested for 1.5 h in 10 mg/ml Dispase (Sigma), 10% FBS in
Puck’s Saline A (PSA) solution as described9. Cells were resuspended
at a density of 2.5 107 cells/ml and plated in high density micromass
cultures, a system favoring chondrogenic differentiation as de-
scribed40,41. Cells were infected in suspension at a multiplicity of infec-
tion (MOI) of 1 with puriﬁed adenovirus expressing Cre Recombinase.
Adenovirus was puriﬁed with the Adeno-X virus mini-puriﬁcation kit
(Clontech). After 20 min, the cell suspension was plated in 10 ml drop-
lets. One hour later, cells were fed media and supplemented with
50 mg/ml ascorbic acid and 1 mM b-glycerol-phosphate. Twelve hours
later, media was exchanged and thereon after every 24 h for a period
of 6 days in culture. RNA was also isolated directly from the cartilage
of newborn cartilage-speciﬁc Rac1 knockout mice as described38.
Real-time reverse-transcriptase polymerase chain reaction
(RT-PCR)
RNA was isolated by the RNeasy kit (QIAGEN) from primary chondro-
cytes 24 h after inhibitor treatment, on days 3, 6 and 9 in the ATDC5 cell
line or on days 1, 3 and 6 of micromass cultures. Twenty-ﬁve nanograms
of RNA was plated per well in quadruplicate and analyzed for gene expres-
sion of CTGF/CCN2, Cyr61/CCN1, Nov1/CCN3, Wisp1/CCN4 and Wisp2/
CCN5. Relative gene expression was determined relative to 18s rRNA and
then normalized to the vehicle control8,42.
Transient transfections
Four hours after primary chondrocytes were plated in monolayer cul-
ture (subconﬂuent), a subset of cells were transfected with various
CTGF/CCN2 promoter constructs linked to secreted alkaline phospha-
tase (SEAP); an 805 bp full length basal promoter upstream of the
TATA box, or mutated basal control element BCE-1, Smad, Ets-1 or
SP1 binding sites19,40e42. A promoter/reporter construct containing mul-
timers of a Smad binding element upstream of the luciferase reporter
gene was a kind gift of Peter ten Dijke (Leiden University)43. Cells
were co-transfected with a plasmid encoding b-galactosidase as trans-
fection control. A Smad responsive reporter (CAGA) linked to ﬁreﬂy lu-
ciferase was also transfected with a Renilla control plasmid under the
control of the SV40 promoter. A DNA/Fugene ratio of 6:1 was trans-
fected as previously described7,33, a relatively efﬁcient transfection pro-
tocol for promoter studies in chondrocytes44. Twelve hours later, media
was changed and cultures were treated with vehicle control or cytocha-
lasin D for a period of 24 h. Alternatively, a subset of cells was trans-
fected with the different CTGF/CCN2 constructs (as described above)
and with an empty vector (pcDNA3.1) or a dominant negative (DN)
Rac1 expression vector.
Western blotting
Protein was isolated from primary chondrocytes treated for 24 h with
the vehicle control, 1 mM cytochalasin D, or 50 mM NSC23766 as previ-
ously described9. Forty micrograms of total protein was separated by
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) and then transferred to a nitrocellulose membrane (Schleicher
and Shull). The membrane was blocked in 5% bovine serum albumin
(BSA)/Tris-buffered saline and 0.01% Tween-20 (TBST) for 1 h at
4C. An antibody directed to CTGF/CCN2 was diluted in 5% BSA/
TBST and incubated with the membrane overnight at 4C. After incuba-
tion with the HRP-conjugated secondary antibody for 1 h, CTGF/CCN2
was visualized by the ECL chemiluminescent kit (Amersham). After
stripping the membrane, b-actin was visualized in order to determine
equal loading.
Statistical analysis
Data collected from real-time PCR are the average of three indepen-
dent trials (long bones from 1 to 2 litters of embryos are equivalent to
one trial) of samples run in quadruplicate. Means were quantiﬁed rela-
tive to 18s rRNA and then data were normalized to vehicle-treated RNA
per trial. Data collected from luciferase construct transfections are an
average of three independent experiments run in quadruplicate.
408 A. Woods et al.: Rac1 regulates CTGF gene expressionRelative light units were determined by dividing ﬁreﬂy luciferase activity
by Renilla control activity, and then data were normalized to the vehicle
control for each promoter construct. Statistical signiﬁcance was deter-
mined by a one- or two-way analysis of variance (ANOVA) with Bonfer-
roni posttest using GraphPad Prism version 4.00 for Windows,
GraphPad Software, San Diego, California, USA, www.graphpad.com.ResultsACTIN CYTOSKELETON AND PATHWAYS REGULATING ACTIN
REGULATES THE EXPRESSION OF THE CCN2 FAMILY
MEMBERSWe ﬁrst examined the effects of pharmacological com-
pounds affecting actin dynamics on mRNA levels of CCN
family members in chondrocytes. Real-time PCR analyses
of chondrocytes treated for 24 h with inhibitors demon-
strated that CTGF/CCN2 gene expression is downregulated
by cytochalasin D treatment, but is not affected by jasplaki-
nolide or inhibition of RhoA/ROCK signaling by Y27632
[Fig. 1(A)]. The closely related family member Cyr61/
CCN1 was downregulated by both cytochalasin D andA B
DC
E
F
Nov1
0
0.5
1
1.5
2
DMSO
R
el
at
iv
e 
N
ov
1 
G
en
e 
Ex
pr
es
sio
n
CTGF
0
0.5
1
1.5
2
2.5
DMSO Y27632 CytD Jasp
R
el
at
iv
e 
CT
G
F 
G
en
e
 
Ex
pr
es
sio
n
0
0.5
1
1.5
2
DMSO
R
el
at
iv
e 
W
isp
2 
G
en
e 
Ex
pr
es
sio
n 
Wisp2
*
*
Y27632 CytD Jasp
Y27632 CytD Jasp
Fig. 1. Actin cytoskeleton and pathways mediating actin regulate the expre
E15.5 long bones were plated in high density monolayer cultures and tre
plakinolide or 50 mM NSC23766. RNA was isolated, and relative mRNA e
PCR in comparison to 18s rRNA. (A) Cytochalasin D treatment results i
jasplakinolide had no effect on CTGF transcripts. (B) Cyr61mRNA levels a
ment, but not affected by jasplakinolide. (C) Nov1 mRNA levels are not
mRNA levels are decreased by all treatments, while (E) Wisp2 mRNA le
of Rac1 activity by NSC23766 resulted in a signiﬁcant decrease in mRNA
gene expression of Nov1. Data shown are average of three independY27632 but not affected by jasplakinolide [Fig. 1(B)].
Nov1/CCN3 was not affected by any of the pharmacological
actin modiﬁers tested [Fig. 1(C)] whileWisp1/CCN4 expres-
sion was decreased by all compounds [Fig. 1(D)]. Wisp2/
CCN5 gene expression was decreased by inhibition of actin
polymerization by cytochalasin D treatment and was not
signiﬁcantly changed with the other actin modiﬁers
[Fig. 1(E)].
We wanted to determine if Rac1 speciﬁcally had any ef-
fect on the gene expression of the CCN family members.
We show that Rac1 inhibition results in a signiﬁcant de-
crease in gene expression of CTGF/CCN2, Cyr61/CCN1,
Wisp1/CCN4 and Wisp2/CCN5 but had no effect on the ex-
pression levels of Nov1/CCN3 [Fig. 1(F)]. These data sug-
gest that each CCN gene is regulated in a unique manner
by the employed compounds. Due to the known skeletal
phenotype of CTGF-deﬁcient mice in vivo and the impact
of loss of CTGF/CCN2 on early chondrogenesis in vitro30,33
and the regulation of CTGF/CCN2 transcript levels by cyto-
chalasin D and Rac1 inhibition, we focused subsequent ex-
periments on this gene.Cyr61
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ssion of CCN family members. Primary chondrocytes isolated from
ated for 24 h with 10 mM Y27632, 1 mM cytochalasin D, 50 nM jas-
xpression for CCN family members was assessed by RT real-time
n a signiﬁcant decrease in CTGF mRNA levels while Y27632 and
re signiﬁcantly decreased by both Y27632 and cytochalasin D treat-
affected by any modiﬁcations to the actin cytoskeleton. (D) Wisp1
vels are only decreased by cytochalasin D treatment. (F) Inhibition
levels of CTGF, Cyr61, Wisp1 and Wisp2 but had no effect on the
ent trials (n¼ 3), run in quadruplicate each, S.E.M., *P< 0.05.
409Osteoarthritis and Cartilage Vol. 17, No. 3RAC1 SIGNALING PROMOTES CTGF/CCN2 GENE EXPRESSIONBecause Rho GTPases have been implicated in regulat-
ing members of the CCN family in other cell types, we ana-
lyzed the effects of overexpressing Rac1, Cdc42 and RhoA
in the chondrocyte cell line ATDC5 on CTGF/CCN2 expres-
sion. CTGF/CCN2 mRNA expression increased stronglyA
B
C
Fig. 2. Rac1 signaling promotes CTGF/CCN2 expression. (A) ATDC5 cells
Rac1, RhoA or Cdc42 and stimulated to differentiate over a period of 9 d
control cells (light gray bars) as the cells became more chondrogenic ove
in a signiﬁcant decrease in CTGF mRNA levels by day 6 of culture. Over
CTGF mRNA levels by day 6 of culture. Addition of cytochalasin D trea
reduced CTGF levels, similar to control. RhoA overexpression (gray
mRNA levels. (B) Mesenchymal cells were isolated from E11.5 Rac1fl/fl m
binase. After plating in micromasses, cultures were allowed to differentiat
decreased by day 3 of culture. (C) RNA was isolated from the cartilage of
a tissue-speciﬁc knockout (Col2-Cre cross). Real-time PCR demonstrates
Data shown are an average of three independent trialsover time, suggesting that CTGF/CCN2 expression is upre-
gulated during chondrogenesis [Fig. 2(A)]. Overexpression
of Rac1 (black bars) resulted in increased mRNA levels of
CTGF/CCN2 while RhoA (dark gray bars) and Cdc42
(gray fade bars) did not have any signiﬁcant effect on
CTGF/CCN2 mRNA expression [Fig. 2(A)]. Additionally,were stably transfected with empty vector or expression vectors for
ays in culture. CTGF mRNA levels signiﬁcantly increase in vector
r time. Inhibition of actin polymerization by cytochalasin D resulted
expression of Rac1 (black bars) resulted in a signiﬁcant increase in
tment to Rac1 overexpressing cells (white fade bars) resulted in
fade bars) and Cdc42 (white fade bars) had no effect on CTGF
ice or controls and infected with adenovirus expressing Cre recom-
e over a period of 4 days. mRNA levels of CTGF were signiﬁcantly
newborn mice that were either wild-type or null for the Rac1 locus in
a signiﬁcant decrease of CTGF mRNA levels in knockout animals.
(n¼ 3), run in quadruplicate S.E.M., *P< 0.05.
410 A. Woods et al.: Rac1 regulates CTGF gene expressionwe show that treatment of vector control cells with 1 mM cy-
tochalasin D (white bars), results in a signiﬁcant decrease in
the levels of CTGF/CCN2 mRNA on days 6 and 9 of culture
[Fig. 2(A)], similar to primary cultures. Meanwhile, the com-
bination of Rac1 overexpression and cytochalasin D treat-
ment (white fade bars) reduces mRNA levels of CTGF/
CCN2 to control levels [Fig. 2(A)], suggesting that actin re-
modeling is required for the effects of Rac1 on CTGF/CCN2
expression.
To further conﬁrm Rac1 involvement in CTGF/CCN2 ex-
pression, we isolated mesenchymal cells derived from mice
homozygote for a Rac1 allele ﬂanked by loxP sites (Rac1fl/fl)
or control animals and infected with adenovirus encoding
Cre recombinase9. Reduction in Rac1 levels in these cells
was previously conﬁrmed9. Whereas wild-type cells showed
a robust increase in CCN2 mRNA expression during the
time period (similar to chondrogenic differentiation of
ATDC5 cells), Rac1-deﬁcient cells showed a marked reduc-
tion in CTGF/CCN2 mRNA levels [Fig. 2(B)]. To further con-
ﬁrm these results, we demonstrated that cartilage of
newborn chondrocyte-speciﬁc Rac1 knockout mice also
displayed a signiﬁcant decrease in CTGF/CCN2 mRNA
levels relative to control littermates [Fig. 2(C)]. Note that
we have previously shown that the effects of NSC23766
is similar to the effects of genetic deletion of the Rac1
gene in chondrocytes38. Collectively, these results further
establish Rac1 as a positive regulator of CTGF/CCN2 ex-
pression levels in chondrocytes.CTGF/CCN2 PROTEIN LEVELS ARE DECREASED BY
CYTOCHALASIN D TREATMENT AND INHIBITION OF RAC1
SIGNALINGAWe wanted to conﬁrm if the inhibition of actin polymeriza-
tion by cytochalasin D treatment also similarly decreased
protein levels of CTGF. We demonstrated by Western blot-
ting that treatment of chondrocytes with 1 mM of cytochala-
sin D resulted in a decrease in the amount of CTGF/CCN2
protein levels in comparison to control cultures [Fig. 3(A)],
which was assessed to be statistically signiﬁcant by densi-
tometry analysis [Fig. 3(B)]. Additionally, Rac1 inhibition by
NSC23766 also decreased CTGF/CCN2 protein levels in
comparison to control cultures [Fig. 3(A) and (B)].B
RAC1 AND ACTIN SIGNALING MEDIATES CTGF/CCN2
TRANSCRIPTION VIA THE SMAD BINDING SITEFig. 3. CTGF protein levels are decreased by cytochalasin D treat-
ment and inhibition of Rac1 signaling. (A) Primary chondrocytes
isolated from the long bones of E15.5 mice were plated in high den-
sity monolayer cultures and treated with 1 mM cytochalasin D or
50 mM NSC23766 (Rac1 inhibitor) for a period of 24 h. Western
blot analyses demonstrate decreased protein levels of CTGF in re-
sponse to both treatments. (B) Densitometry shows that the reduc-
tions in protein levels relative to b-actin are signiﬁcant when either
actin polymerization or Rac1 signaling is inhibited. Data shown are
representative of three independent trials (n¼ 3).We wanted to assess if the decreases in CTGF/CCN2
mRNA levels by inhibition of Rac1 or actin polymerization
were due to decreases in transcription or a destabilization
of mRNAs. We started by transfecting a full length CTGF/
CCN2 promoter (805 bp upstream of the TATA box) linked
to SEAP into primary chondrocytes plated in high density
monolayer culture and co-transfected an empty vector as
the control or an expression vector expressing DN Rac1.
DN Rac1 expression resulted in signiﬁcantly reduced activ-
ity of the full length CTGF/CCN2 promoter [Fig. 4(A)], con-
sistent with our ﬁndings at the mRNA levels. Similarly,
inhibition of actin polymerization by cytochalasin D resulted
in decreased activity of the CTGF/CCN2 full length pro-
moter [Fig. 4(B)]. These data suggest that the decrease in
mRNA levels of CTGF/CCN2 in response to inhibition of
Rac1 signaling or cytochalasin D treatment is due to de-
creased activity of the CTGF/CCN2 promoter.
We then wanted to determine which elements in the
CTGF/CCN2 promoter are responsible for mediating the de-
crease in CTGF/CCN2 transcription, using the full lengthpromoter harboring point mutations in the BCE-1, Smad,
Ets-1 or Sp1 sites45. Transient transfection studies demon-
strated that mutation of the Smad site largely abolished the
promoter response to DN Rac1 [Fig. 4(A)], whereas all
other point mutations tested did not affect the decrease in
CTGF/CCN2 promoter activity in response to DN Rac1
[Fig. 4(A)]. The decrease in CTGF/CCN2 transcription in re-
sponse to cytochalasin D treatment also appeared to re-
quire the Smad binding site [Fig. 4(B)]. However, unlike
Rac1 signaling, cytochalasin D effects were also disrupted
by mutating the BCE-1 and Ets-1 sites [Fig. 4(B)].INHIBITION OF RAC1 SIGNALING DECREASES A SMAD
RESPONSIVE REPORTERTo further conﬁrm the role of Smad signaling in mediating
Rac1 regulation of the CTGF/CCN2 promoter; we trans-
fected a Smad responsive reporter into primary chondro-
cytes and treated cells with a vehicle control or 50 mM of
NSC23766. Our results show that the activity of the Smad
reporter was decreased when Rac1 signaling was inhibited
by NSC23766 in chondrocytes (Fig. 5). These data further
suggest that the regulation of CTGF/CCN2 by Rac1 signal-
ing is mediated via Smads.Discussion
Although it has been previously shown that CTGF/CCN2
is an important regulator of chondrocyte differentiation and
therefore endochondral bone formation46; the signaling
pathways that mediate CTGF/CCN2 expression in chondro-
cytes have not been fully investigated. In this study, we
AB
Fig. 4. Rac1 and actin signaling mediate CTGF transcription via the Smad binding site. (A) Primary chondrocytes isolated from the long bones
of E15.5 mice were plated in high density monolayer cultures and co-transfected with a full length (805 bp) CTGF promoter or with promoters
harboring point mutations in speciﬁc binding sites (Smad, BCE-1, Ets-1 and Sp1) linked to SEAP, a control b-galactosidase vector under the
control of a CMV promoter and an empty vector for control or an expression vector for DN Rac1. After 48 h, SEAP and b-galactosidase activity
were quantiﬁed and relative SEAP activity was calculated. Vector controls were set to a value of 100% and DN Rac1 SEAP activity was ex-
pressed as percent inhibition relative to vector controls. DN Rac1 signiﬁcantly decreased the activity of the full length CTGF promoter. All site
speciﬁc point mutant constructs demonstrated the same decrease in promoter activity with inhibition of Rac1 activity with the exception of the
Smad mutant that showed no signiﬁcant decrease in promoter activity. (B) Primary chondrocytes were co-transfected with the full length CTGF
promoter and mutant promoters and then treated with DMSO vehicle or 1 mM cytochalasin D. After 48 h, SEAP and b-galactosidase activity
were quantiﬁed and relative SEAP activity was calculated. DMSO controls were set to a value of 100 and cytochalasin D treatment was ex-
pressed as percent inhibition relative to controls. Inhibition of actin polymerization by cytochalasin D treatment resulted in a signiﬁcant de-
crease of the full length CTGF promoter. Only the Sp1 point mutant construct demonstrated a similar decrease in promoter inhibition while
the Smad, BCE-1 and Ets-1 mutants were resistant to cytochalasin D promoter inhibition. Data shown are the average of three independent
trials (n¼ 3) run in triplicate, mean percent inhibition S.E.M., *P< 0.05.
411Osteoarthritis and Cartilage Vol. 17, No. 3have shown that CTGF/CCN2 expression is regulated by
Rac1 signaling and actin organization in chondrocytes.
More speciﬁcally, inhibition of actin polymerization by cyto-
chalasin D results in a decrease of CTGF/CCN2 mRNA and
protein levels. We have also demonstrated that overexpres-
sion of Rac1 results in higher levels of CTGF/CCN2 expres-
sion, and that inhibition of Rac1 activity both
pharmacologically or genetically reduces levels of CTGF.
Furthermore, our studies show that the increase in CTGF/CCN2 transcript levels in response to Rac1 overexpression
is inhibited by cytochalasin D treatment, suggesting that ac-
tin dynamics mediate the CTGF/CCN2 response to Rac1.
Our studies demonstrate that the response of the CTGF/
CCN2 gene to Rac1 signaling is mediated by the Smad
binding site in the CTGF/CCN2 promoter. The effects of in-
hibiting actin polymerization on CTGF/CCN2 expression
levels also require the Smad binding site as well as the
BCE-1 and Ets-1 sites in the CTGF/CCN2 promoter. These
Fig. 5. Inhibition of Rac1 signaling decreases a Smad responsive
reporter. Primary chondrocytes were co-transfected with a Smad
responsive reporter linked to ﬁreﬂy luciferase and a control plasmid
expressing Renilla luciferase under the control of SV40. Inhibition
of Rac1 signaling by NSC23766 results in a signiﬁcant decrease
of Smad activity. Data shown are an average of three independent
trials (n¼ 3) run in triplicate, relative light units S.E.M., *P< 0.05.
412 A. Woods et al.: Rac1 regulates CTGF gene expressiondata suggest the involvement of TGFb signaling in the Rac1
actin-dependent control of CTGF/CCN2 transcription in
chondrocytes. TGFb/Smad signaling is known to promote
early stages of chondrocyte differentiation47 and promotes
chondrocyte maturation48. Rac1 signaling has also been
found to promote multiple stages of chondrocyte differentia-
tion9,38. Interestingly, some similarities exist between carti-
lage-speciﬁc Rac1-deﬁcient animals and CTGF/CCN2
knockout mice. For example, both models display deﬁcient
angiogenesis in long bones and delayed endochondral os-
siﬁcation30,38. Our results are consistent with previous ob-
servations using mesangial cells that disrupting the actin
cytoskeleton with cytochalasin D selectively decreased
basal and TGFb1 induced cell-layer collagens I and IV ac-
cumulation and Smad phosphorylation49.
We are not the ﬁrst to show that CTGF/CCN2 expression
is regulated by the actin cytoskeleton and by various mem-
bers of the Rho family; however, we are the ﬁrst to demon-
strate the involvement of Rac1 and the actin cytoskeleton in
regulating CTGF/CCN2 speciﬁcally in chondrocytes. More
importantly, we identify the speciﬁc region of the CTGF/
CCN2 promoter that is responsive to actin-dependent
Rac1 signaling. Intriguingly, the Smad binding site of the
CTGF/CCN2 promoter has been previously shown to be im-
portant in the regulation of basal CTGF/CCN2 promoter ac-
tivity in mesangial, but not scleroderma cells, emphasizing
that CTGF/CCN2 promoter activity is regulated in fashion
depending on the cell-speciﬁc context29.
Our studies also show that CTGF/CCN2 transcript levels
are only regulated by Rac1 signaling in chondrocytes,
whereas overexpression of RhoA (or inhibition of the Rho
effectors ROCK1/2 by Y27362) have no effect. In many
other cells types, CTGF/CCN2 is regulated in response to
both RhoA/ROCK signaling and Cdc4250,51.
Cyr61/CCN1 and CTGF/CCN2 are co-regulated in many
other cell systems52,53. However, in our studies, we show
that cytochalasin D and inhibition of Rac1 activity results in
decreased levels of both CTGF/CCN2 and Cyr61/CCN1
while Y27632 only inhibitsCyr61/CCN1mRNA levels. More-
over, none of the inhibitors tested reduced Nov1/CCN3
mRNA. Collectively, these results suggest independent ef-
fects of actin dynamics on different CCN family members in
chondrocytes. In chondrocytes, Cyr61/CCN1 is downregu-
lated in chondrocyte differentiation, but is upregulated duringfracture healing54,55. Also, CTGF/CCN2 has been found to
regulate certain aspects of chondrogenesis and the early
transition from a mesenchymal cell to a chondrocyte23,33.
Overall, our data show that actin dynamics and Rac1 reg-
ulate CCN family expression in chondrocytes in a gene- and
cell type-speciﬁc manner, and that altered levels of CTGF/
CCN2, and possibly of other CCN proteins as well, could
be expected to contribute to the defects observed in carti-
lage-speciﬁc Rac1 KO mice and to the effects of actin mod-
ulators on chondrocytes in vitro and in vivo. Our studies
also have implications to both the described destructive
and anabolic functions of CTGF/CCN2 in osteoarthritis
where modulation of CTGF/CCN2 expression might be
used therapeutically.Conﬂict of interest
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